drug laws

Biotech company Disc Medicine is the subject of investor investigations following an FDA letter connected to its drug development work. Law firms and shareholder groups are reportedly looking into whether the company made misleading statements about regulatory progress. The news has put pressure on the stock and left investors watching for further disclosures about the FDA's concerns.